Initial research suggest that Retatrutide – a dual agonist of gut hormone and glucose-dependent insulinotropic polypeptide receptors – may provide a considerable improvement in metabolic loss therapies. Beyond existing therapies, Retatrutide appears to affect appetite and metabolic expenditure via separate mechanisms . Despite further investig